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Abstract
Background: There is little existing research to guide researchers in estimating the minimum
number of measurement occasions required to obtain reliable estimates of serum estrogens,
progesterone, gonadotropins, sex hormone-binding globulin (SHBG), and urinary estrogen and
progesterone metabolites in premenopausal women.
Methods: Using data from a longitudinal study of 34 women with a mean age of 42.3 years (SD =
2.6), we calculated the minimum number of measurement occasions required to obtain reliable
estimates of 12 analytes (8 in blood, 4 in urine). Five samples were obtained over 1 year: at baseline,
and after 1, 3, 6, and 12 months. We also calculated the percent of true variance accounted for by
a single measurement and intraclass correlation coefficients (ICC) between measurement occasions.
Results: Only 2 of the 12 analytes we examined, SHBG and estrone sulfate (E1S), could be
adequately estimated by a single measurement using a minimum reliability standard of having the
potential to account for 64% of true variance. Other analytes required from 2 to 12 occasions to
account for 81% of the true variance, and 2 to 5 occasions to account for 64% of true variance.
ICCs ranged from 0.33 for estradiol (E2) to 0.88 for SHBG. Percent of true variance accounted for
by single measurements ranged from 29% for luteinizing hormone (LH) to 92% for SHBG.
Conclusions: Experimental designs that take the natural variability of these analytes into account
by obtaining measurements on a sufficient number of occasions will be rewarded with increased
power and accuracy.
Background
Several active research programs are investigating the risk
associated with serum estrogens, gonadotropins and uri-
nary sex hormone metabolites for a variety of diseases in-
cluding breast cancer [1], endometrial cancer [2], and
osteoporosis [3]. The results of the few published studies
suggest that the natural temporal variability (true varia-
tion over time, not variation due to storage or other fac-
tors) of some serum estrogens, gonadotropins and urinary
sex hormone metabolites is sufficiently great that a single
measurement occasion may be inadequate to ensure a re-
liable estimate [4–6]. Published intraclass correlation co-
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efficients (ICC) vary between 0.06 and 0.62 for estradiol
(E2) and between 0.52 and 0.69 for estrone (E1) [4]. Only
the percent of free E2 and of SHBG-bound E2 have been
found to be sufficiently reliable to account for as much as
50% of the variance in the true mean (ICC > 0.7).
The term reliability can refer either to the consistency of a
measuring procedure or to the temporal stability of the
target of measurement [7]. The definition of temporal re-
liability used in this study includes both those dimen-
sions, but emphasizes the latter. While researchers can
control error due to insufficient repeated measures by in-
creasing the number of measurement occasions, obtain-
ing measurements is expensive. It is therefore useful to
have evidence-based guidelines for estimating the mini-
mum number of occasions required to obtain a given de-
gree of reliability for a particular analyte.
All types of measurement error distort, confound, or at-
tenuate the tests of association that constitute one of the
primary products of research [8,9]. Figure 1, though not
exhaustive, shows the sources of variance in a measure-
ment and the interrelationships between error and tests of
model fit or significance.
The relation of a measurement to the object being meas-
ured can be represented as: σO = σT + σE, where σO = var-
iance in the observed measurement of the target, σT =
variance in the true value of the target, and σE = random
variance, or error. If the true value of the target is invariant
across measurements, i.e., if σO = σE, the observed vari-
ance will be purely a function of the unreliability of the
measuring instrument. Conversely, if perfectly error-free
measurement of the target could be assumed, i.e., if σE =
0, then σO = σT and the observed variance would be purely
a function of the temporal stability of the target. If σE ≠ 0
and σT ≠ 0, the observed variance will be a function of
both the temporal stability of the target and of the unreli-
ability of the measuring instrument.
Measurement error can result from a variety of factors, in-
cluding true variance not captured by a particular meas-
urement strategy, which may complicate the
interpretation of temporal reliability estimates. These oth-
er factors include variance due to: fluctuations across cycle
phases within each woman's menstrual cycle [10]; dura-
tion of sample storage prior to analysis [11]; limitations of
the assay; multiple analysis batches [10]; multiple types of
assays [12]; and multiple laboratories [10]. Ideally, esti-
mates of as many sources of error as possible should be in-
cluded when considering the impact of temporal
reliability on measurement strategy. The objective of this
study was to determine the following for various serum es-
trogens, gonadotropins, and urinary sex hormone metab-
olites: the minimum number of repeated measurements
required for reliable estimates; the ICCs; and the amount
of true variance accounted for by single measurements.
Methods
Experimental design
The data for this study come from a randomized double-
blind study investigating the effects of a 100 mg/day soy
isoflavone regimen on estrogen levels in 34 premenopau-
sal women. A detailed description of the study design and
the results of the intervention were reported in Maskari-
nec et al., 2002).)[13]. The Committee on Human Studies
at the University of Hawaii approved the study protocol.
Written informed consent was obtained from each sub-
ject, prior to participation. The study group consisted of
17 premenopausal women per group. Four women left
the study before the end of the year and another was able
to give only four blood draws for health reasons. Eligibil-
ity criteria included: an age range of 35–46 years; an aver-
age intake of less than 7 servings of soy foods per week; no
prior cancer diagnosis (except basal cell skin carcinoma);
no use of oral contraceptives or hormone preparations
within the past three months; no intention of becoming
pregnant within the next year; an intact uterus and ova-
ries; self-defined regular menstrual periods; no serious
medical condition. Subjects had a mean age of 42.3 years
(SD = 2.6), and a mean weight of 65.6 kg (SD = 12.8).
Subjects were ethnically diverse: 18 were Caucasian; 6
were Chinese; 5 were Japanese; 5 were Hawaiian.
Sample collection
Subjects were asked to donate 5 urine and blood samples,
one at baseline and one after 1, 3, 6, and 12 months of
participation. All samples were collected approximately 5
days after the ovulation (approximately day 19 in a 28 day
cycle). Subjects used ovulation kits (Ovuquick test kits
from Quidel, La Jolla, CA) to determine the time of ovu-
lation. This kit detects the mid-cycle rise of LH using
morning urine with a sensitivity of 35 mIU/mL of LH and
its predictive validity with respect to ovulation has been
estimated as 93% [14]. Although the use of a minimum
progesterone value to exclude data from anovulatory cy-
cles from the analyses helped ensure acquisition of the
mid-luteal phase samples, only 52% of samples were ob-
tained on exactly the 5th day from ovulation. Ninety-one
percent were obtained between the 4th and the 6th day
from ovulation. Blood samples were drawn at a commer-
cial laboratory, in the morning between 7 and 9 o'clock to
control for circadian rhythm in hormone levels. Serum
and urine samples were stored at -80°C after separation
and aliquoting.BMC Women’s Health 2002, 2 http://www.biomedcentral.com/1472-6874/2/13
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Serum analysis
Hormone assays were conducted at the Department of
Obstetrics and Gynecology, University of Southern Cali-
fornia (Los Angeles, CA) in the Reproductive Endocrine
Research Laboratory. The analyses for E2, free E2, E1, E1S,
progesterone, SHBG, follicle stimulating hormone (FSH),
and LH were conducted in 2 batches. Samples of these an-
alytes collected at baseline, month 1 and month 3 were
analyzed in batch 1, and 6-month and 12-month samples
were analyzed in batch 2 one year later. E2, E1, progester-
one, FSH, LH, and SHBG were quantified in serum by spe-
cific and sensitive radioimmunoassays (RIAs). Prior to
Figure 1
Total observed varianceBMC Women’s Health 2002, 2 http://www.biomedcentral.com/1472-6874/2/13
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RIA, E1 and E2 were first extracted with ethyl acetate: hex-
ane (2:3) and then purified by Celite column partition
chromatography, using ethylene glycol as stationary
phase [15]. E1 and E2 were eluted off the column with
15% and 40% toluene in isooctane, respectively. 3H-E1
and 3H-E2 were used as internal standards to follow pro-
cedural losses. FSH and LH levels were determined using
an immunoradiometric assay (IRMA). E1S, progesterone
and SHBG were measured by direct RIAs using kits ob-
tained from Diagnostic Systems Laboratories, Webster,
Texas. Free E2 (non-SHBG or albumin-bound-E2) was de-
termined by calculation using a computerized algorithm
described previously).)[16]. The majority of intra-assay
CVs for all analytes were below 10% (Table 1) indicating
good quality control in the laboratory. They ranged from
<0.5% for SHBG to 13.0% in the low concentration range
of batch 1 for E1.
Urine analysis
Urine samples were analyzed for estrone-3-glucuronide
(E1-G), pregnanediol-3-glucuronide (PDG), 16α-hydrox-
yestrone (16α-OHE1) and 2-hydroxyestrone (2-OHE1).
E1-G and PDG were measured directly in urine by enzyme
immunoassay [17]. Commercially available enzyme-
linked immunosorbent assay kits (Estramet: Immuna
Care Corporation, Bethlehem, PA) were used to deter-
mine levels of 16α-OHE1 and 2-OHE1 in urine [18]. All
results are relative to creatinine excretion.
Statistical analysis
The SAS statistical software package version 8.2 (SAS Insti-
tute Inc., Cary, NC, 1999–2001) was used to perform the
statistical analyses. All statistics were computed using
logged values when raw values were not normally distrib-
uted. To ensure that all measurements in the analysis were
from the same time in the menstrual cycle, observations
were only included if the concurrent progesterone values
were at least 5 ng/mL, a minimum value after an ovula-
tion has occurred. Because analyses for 8 of 12 analytes
were conducted in two batches, we included considera-
tion of error due to between batch variance in our analysis
of the temporal stability of these analytes. Therefore, esti-
mates of temporal stability for the 8 analytes were calcu-
lated for the total number of samples and for the first and
second batches separately.
Two types of estimates of the number of measurement oc-
casions (O) necessary to obtain an adequately reliable es-
timate were computed. The first, the relative type (OR)
includes the between-subject variance. OR was computed
Table 1: Coefficients of variation for all analytes
Analyte Biological 
Component
Batch 1 Mean of QC 
Value
CV (%) Batch 2 Mean of QC 
Value
CV (%)
Estradiol (pg/mL) Plasma 53 9.0 38 9.4
114 7.0 77 9.9
202 9.0 -- --
Estrone (pg/mL) Plasma 82 13.0 105 7.8
1 5 88 . 0 2 6 27 . 5
354 7.0 -- --
Estrone-sulfate (ng/mL)* Plasma 1.1 10.9
8.8 11.6
Progesterone (ng/mL) Plasma 4.0 7.0 1.1 2.6
12.0 8.0 9.3 6.1
SHBG (nM/L)* Plasma 74 2.0
FSH (mIU/mL)* Plasma 5.96 7.4
16.7 10.4
54.2 5.6
LH (mIU/mL)* Plasma 1.97 9.1
19.2 1.4
47.9 1.6
E1-G (ng/mL)* Urine 16.2 7.0
33.6 10.3
PDG (ug/mL)* Urine 0.6 5.6
3.0 2.6
2-OHE1 (ng/mL)* Urine 4.5 2.3
16α-OHE1 (ng/mL)* Urine 2.3 11.6
*Both batches. QC = quality control. SHBG = Sex hormone-binding globulin. FSH = follicle stimulating hormone. LH = luteinizing hormone. E1-G = 
estrone-3-glucuronide. PDG = pregnanediol-3-glucuronide. 2-OHE1 = 2-hydroxyestrone. 16α-OHE1 = 16α-hydroxyestrone.BMC Women’s Health 2002, 2 http://www.biomedcentral.com/1472-6874/2/13
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using the formula proposed by Nelson et al. [19]:
 where r is the correlation between the
observed and the true mean analyte values for an individ-
ual over a year, sW
2 is the within-subject variance, and sB
2
is the between-subject variance. Setting r to 0.9 results in
a calculation of the number of measurement occasions re-
quired to obtain an estimate that would account for 0.92
or 81% of the true variance in the target. Ninety-five per-
cent confidence intervals (95% CI) for OR were computed
using a published method).)[20].
The second estimate of the number of measurement occa-
sions necessary to obtain an adequately reliable estimate,
the absolute type (OA), includes only within-subject vari-
ance. OA was calculated as  , where
σw is the within-subject variance [21]. By adjusting the de-
nominator, this method allows for the desired approxi-
mation to the true mean to be specified as a percentage.
Setting the denominator to 0.2 results in a calculation of
the number of occasions required to obtain an estimate
that is within 20% of the true mean. A SAS macro using
Proc Varcomp and Proc Means to produce estimates of
OR, OA, and related statistics is available from the authors.
ICCs measure the proportion of variance attributable to
targets of measurement as a ratio of within-subject vari-
ance to total variance [22] and are suitable to compare
variables of the same measurement class [23]. We com-
puted two types of ICCs using the notation developed by
Shrout and Fleiss [22]: ICC(2,1) was computed for each
analyte using all 5 measurement occasions to estimate the
temporal reliability of the analyte; ICC(2,k) was comput-
ed between batches to estimate the contribution of be-
tween-batch variance to the temporal reliability estimate.
ICC(2,1)  was computed as ICC(2,1)  =
, 
where BMS is the between-subjects mean square, EMS is
the error mean square, k is the number of observations,
OMS  is the observations mean square, and n  is the
number of subjects [22]. ICC(2,k)  was computed as
ICC(2,k) = . 
We applied the formulas by Shrout and Fleiss [22] to ob-
tain 95% CIs.
To estimate the percentage of true variance accounted for
by a single measurement, we assumed that the best avail-
able estimate of the true variance was the total variance for
all occasions.
After calculating the Pearson correlation of each occasion
with all other occasions, we considered the squared aver-
age of these correlations as the estimate of the most likely
percent of true variance for which a single occasion could
account. We used the formula  , where
% σT is the percent of true variance, rT is the Pearson cor-
relation of each occasion with the total of all other occa-
sions, and o is the number of occasions.
Results
Overall means, number of samples, and means by meas-
urement occasion for all analytes (Table 2) indicate the
overall stability for the analytes over one year. Although
estrogen and progesterone levels were on the average 7%
higher and gonadotropins and urinary sex hormone me-
tabolites 10% lower in the intervention than in the con-
trol group (data not shown), none of the differences was
even close to statistical significance (p values ranged from
p = 0.16 to p = 0.90 for Estrone-sulfate and Estrone respec-
tively). Because of this homogeneity, results in this study
were collapsed across experimental groups. The decrease
in E2 and E1 are the result of laboratory drift and were in-
dependent of intervention status).)[13].
The measurement occasions required to obtain a reliable
estimate differed considerably by analyte (Table 3). Using
the relative method to account for 81% of the true vari-
ance, the number of occasions required ranged from OR =
0.48 to OR = 11.43 (for SHBG and E1 respectively). To ac-
count for 64% of the true variance, the number of occa-
sions ranged from OR = 0.20 to OR = 4.77 (for SHBG and
E1 respectively). Using the absolute method, the number
of occasions required to obtain an estimate to within 20%
of the true mean, ranged from OA = 0.34 to OA = 10.27
(for E2 and PDG respectively). It appears that, except for
SHBG and E1S, using a single measurement for any of the
analytes in this analysis may be problematic for the typical
purposes of epidemiological research because the results
of typical epidemiological research center on analyses of
the mean value obtained from one group vs. the mean val-
ue obtained from another, e.g. a group of cases or an in-
tervention group vs. a control group.
Figures 2 to 4 illustrate the different relationship of be-
tween- to within-subject variance and the corresponding
difference between OR and OA.
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Table 2: Basic descriptive data for all measurement occasions of all analytes
All Measurements Means for Each Measurement Occasion
Analyte N M (SD) 1 (BL) 2 (1 mo) 3 (3 mo) 4 (6 mo) 5 (1 yr)
Estradiol (pg/mL) 162 133.32 (51.41) 141.44 140.12 151.78 114.70 116.66
Free Estradiol (pg/mL) 159 3.22 (1.21) 3.44 3.34 3.58 2.74 2.95
Estrone (pg/mL) 162 103.74 (34.77) 115.82 115.29 122.59 81.24 80.83
Estrone-sulfate (ng/mL) 160 4.20 (2.44) 4.74 4.81 4.16 3.80 3.41
Progesterone (ng/mL) 162 9.81 (4.89) 10.09 8.87 11.09 10.16 8.76
SHBG (nmol/mL) 159 48.56 (21.18) 49.81 50.01 50.49 46.15 45.73
FSH (mIU/mL) 159 4.78 (4.21) 3.68 4.89 4.77 5.83 4.73
LH (miu/ml) 161 5.12 (4.34) 4.46 6.46 5.56 4.82 4.18
E1-G (ng/ml) 164 27.74 (20.79) 28.34 31.04 26.06 27.50 25.43
PDG (ug/ml) 164 3.47 (2.15) 3.93 3.23 3.67 3.36 3.11
2-OHE1 (ng/ml) 164 13.76 (8.01) 13.32 14.55 13.07 15.10 12.65
16α-OHE1 (ng/ml) 164 6.94 (5.18) 6.78 6.97 6.42 8.77 5.62
Measurements 1–3 were analyzed in batch 1 and measurements 4 & 5 were analyzed in batch 2. SHBG = Sex hormone-binding globulin. FSH = fol-
licle stimulating hormone. LH = luteinizing hormone. E 1-G = estrone-3-glucuronide. PDG = pregnanediol-3-glucuronide. 2-OHE1 = 2-hydrox-
yestrone. 16α-OHE1 = 16α-hydroxyestrone.
Table 3: Minimum occasions required to obtain a reliable estimate, intraclass correlation coefficients, and percent of true variance 
accounted for by single measurements
Analyte Occasions (samples) Measurement Occasions Required ICC(2,1) (95% CI) % of True Variance 
Accounted for by a 
Single Occasion 
(Range)
To Account for 81% 
of True Variance
To be Within 20% of 
True Mean
Relative Method 
(95% CI)
Absolute Method
Estradiol 5 (100) 8.26 (4.53–13.88) 0.34 0.33 (0.18-0.51) 37 (18-74)
Free Estradiol 5 (85) 5.32 (2.92-8.94) 2.00 0.41 (0.26-0.59) 48 (29-72)
Estrone* 3 (60) 11.43 (6.26-19.20) 0.37 0.51 (0.30-0.69) 50 (14-56)
Estrone-sulfate 5 (90) 1.42 (0.78-2.38) 2.03 0.71 (0.58-0.82) 74 (53-77)
Progesterone 5 (100) 5.15 (2.82-8.65) 8.90 0.40 (0.25-0.58) 40 (27-50)
SHBG 5 (85) 0.48 (0.26-0.80) 1.78 0.88 (0.81-0.93) 92 (84-96)
FSH 5 (85) 5.11 (2.80-8.59) 2.63 0.40 (0.25-0.58) 37 (22-66)
E1-G 5 (100) 3.88 (2.13-6.52) 0.92 0.47 (0.32-0.64) 45 (29-55)
LH 5 (95) 8.38 (4.59-14.07) 8.08 0.30 (0.15-0.48) 29 (17-62)
PDG 5 (100) 5.17 (2.84-8.69) 10.27 0.40 (0.25-0.58) 32 (15-56)
2-OHE1 5 (100) 4.21 (2.31-7.07) 1.57 0.46 (0.30-0.63) 16 (4-40)
16α-OHE1 5 (100) 2.71 (1.48-4.55) 2.44 0.56 (0.41-0.71) 46 (14-79)
Note: includes only complete observations where progesterone > 5 ng/mL; logarithmic transformations of values were used if raw values were not 
normally distributed. * Calculations based on batch 1 only due to high inter-batch variance. SHBG = Sex hormone-binding globulin. FSH = follicle 
stimulating hormone. LH = luteinizing hormone. E1-G = estrone-3-glucuronide. PDG = pregnanediol-3-glucuronide. 2-OHE 1 = 2-hydroxyestrone. 
16α-OHE 1 = 16α-hydroxyestrone.BMC Women’s Health 2002, 2 http://www.biomedcentral.com/1472-6874/2/13
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In the case of SHBG (Figure 2), within-subject variance is
small relative to between-subject variance. There is little
variation within subjects relative to the variation between
subjects, resulting in small OR and OA estimates (0.48 and
1.78 respectively). The PDG values (Figure 3) illustrate the
case in which within subject variation is high and overlap
one another considerably, resulting in relatively large OR
and OA estimates (5.17 and 10.27 respectively). Finally,
Figure 4 depicts the case in which within-subject variance
is small, but so is the variance between subjects. In this
case, the small within-subject variance results in a small
OA estimate (0.34), but because the within-subject vari-
ance is not small relative to the between-subject variance,
the OR is relatively large (8.26).
Because ICCs include both within- and between-subject
variance, ICCs closely followed OR rather than OA esti-
mates.ICC(2,1) ranged from ICC(2,1) = 0.30 to ICC(2,1)
= 0.88 (for LH and SHBG respectively, Table 3). The intra-
class correlation coefficient ICCs for absolute agreement
between the two analysis batches ranged from ICC (2,1) =
0.47 to ICC (2,1) = 0.96 (for E1 and SHBG respectively,
Table 4). Estimates of ICCs were, generally, consistent
across batches, with similar estimates based on analysis of
all 5 occasions and for estimates based on each batch. The
between batch ICC for E1, however, was less than 0.5, sug-
gesting that the batch 1 ICC may be a better indicator than
the ICC based on all samples. The percent of true variance
accounted for by a single measurement ranged from 29%
to 92% for LH and SHBG respectively.
Discussion
We have provided estimates to the minimum number of
measurement occasions required to ensure adequate reli-
ability for two types of experimental aims. Analyses in ep-
idemiologic studies involve calculations in which
between-subject as well as within-subject variance is im-
portant. Therefore, OR will usually be the appropriate in-
dex of the minimum number of occasions needed to
obtain a reliable estimate. Estimates of OR based on our
sample suggest that only SHBG and E1S had sufficient
temporal stability to be adequately reliable with a single
measurement when the desired amount of variance to ac-
count for was set as low as 64%. A single measurement of
Figure 2
Sex hormone-binding globulin values for all participants by measurement occasionBMC Women’s Health 2002, 2 http://www.biomedcentral.com/1472-6874/2/13
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any of the other analytes would be unlikely to account for
even 50% of the true variance. For cases in which the with-
in-subject variance is the only variance of interest, e.g.,
when the measured value of an analyte will be compared
with a fixed standard, OA will be the appropriate index.
The omission of between-subject variance from the for-
mula for calculating this statistic produces very different
results from OR. Several of the analytes that were ade-
quately reliable with a single measurement or very few
measurements, when between-subject variance was a fac-
tor, required higher numbers of measures when only
within-subject variance was involved and vice versa.
This study confirms previous findings that SHBG may be
reliably measured in premenopausal women using a sin-
gle occasion. It also indicates that E1S may be reliably
measured using one sample only. More importantly, our
results suggest that none of the other analytes examined
meet minimal reliability requirements that would permit
confidence in single measures. These results are in agree-
ment with the wide range if ICCs reported in previous
studies [4–6]. Our conclusions are limited to the collec-
tion of samples at midluteal phase, however, and may not
generalize to other phases of the menstrual cycle.
The use of ICCs to estimate the agreement between analy-
sis batches differs from their use as an index of temporal
reliability. The appropriate type of ICC for this purpose
uses a mean of several values rather than single values and
is typically higher than that calculated using single values.
Though the ICCs between batches were higher than those
estimating temporal reliability, they were relatively low,
demonstrating the importance of measuring all samples
in one batch when possible. As was previously noted [11],
error due to time in storage will affect estimates of tempo-
ral reliability. Analyzing in multiple batches is one means
of decreasing this source of error, but runs the risk of in-
creasing error due to multiple batches. Until better esti-
mates of the impact of storage time on each of these
analytes are available, however, it will be difficult to draw
conclusions about whether error due to multiple analysis
batches or error due to storage time has the more detri-
mental effect on temporal reliability.
Figure 3
Pregnanediol-3-glucuronide values for all participants by measurement occasionBMC Women’s Health 2002, 2 http://www.biomedcentral.com/1472-6874/2/13
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Several sources of error are effectively beyond researchers'
capacity to control. For example, the validity and reliabil-
ity of the best assay available for measuring a given ana-
lyte cannot be increased through improving study design.
Other sources of error, however, can be dramatically re-
duced through the use of appropriate designs. These strat-
egies may include, increasing the sample size to reduce the
impact of random error, analyzing all samples in one
batch, and using a sufficient number of repeated measures
to obtain an adequately reliable estimate. It is also possi-
Figure 4
Logged estradiol values for all participants by measurement occasion
Table 4: Intraclass correlation coefficients between batches for analytes analyzed in 2 batches
Analyte ICC(2,k) 95% CI
Estradiol 0.60 -0.03-0.83
Free Estradiol 0.70 0.24-0.87
Estrone 0.47 -0.18-0.79
Estrone-sulfate 0.91 0.77-0.96
Progesterone 0.78 0.58-0.88
SHBG 0.96 0.88-0.99
FSH 0.76 0.57-0.88
LH 0.65 0.36-0.82
Batch 1: 3 occasions over ≈ 3 months. Batch 2: 2 occasions over ≈ 6 months. Total: 5 occasions over ≈ 1 year. SHBG = Sex hormone-binding glob-
ulin. FSH = follicle stimulating hormone. LH = luteinizing hormone. E1-G = estrone-3-glucuronide. PDG = pregnanediol-3-glucuronide. 2-OHE1 = 2-
hydroxyestrone. 16α-OHE1 = 16α-hydroxyestrone.BMC Women’s Health 2002, 2 http://www.biomedcentral.com/1472-6874/2/13
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ble, though not uncontroversial, to control error statisti-
cally by correcting for attenuation using validation data
[24].
Several improvements, in addition to a larger sample and
more repeated measures, would have increased confi-
dence in the results of our study. First, if the effects of stor-
age time on the analytes were known, we could have taken
into account the contributions of this source of variance
to our temporal reliability estimates and distinguished its
impact from that due to assay reliability. Second, obtain-
ing blood and urine samples on day 5 following ovulation
was most appropriate for the measurement of progester-
one and near-optimal for SHBG, but may not have been
the best day to obtain estimates of the other analytes [25].
Third, though our data were drawn from an intervention
study in which no results approached significance, a more
clearly homogeneous sample would have been preferable.
Fourth, variation in menstrual cycle length and variance
due to pulsatility of excretion were additional sources of
error.
Finally, our estimates were based on targets that changed
across measurements, and we could not assume error-free
measurements. Consequently, we were not able to pre-
cisely distinguish between the contributions of assay reli-
ability and the contributions of each analyte's natural
variability to our estimates of temporal reliability. Howev-
er, despite some limitations, this study provided signifi-
cant new insights into the variability of sex hormones,
gonadotropins, and urinary hormone metabolites in pre-
menopausal women during a one-year period. Our esti-
mates of temporal reliability represent the combined
computation of the consistency of a measure across re-
peated measurements and the temporal fluctuations in
the target of measurement.
Conclusions
Given the relatively large sample size for this analysis and
the strictly controlled protocol to collect samples on the
same day of the menstrual cycle, our results will be useful
for designing future research projects exploring the role of
sex hormones in the etiology of cancer and other diseases.
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